Lymphoma, Non-Hodgkin's
Oncology·MeSH: Lymphoma, Non-Hodgkin
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| LY4584180 | ELI LILLY & Co (LLY) |
Frequently asked questions
How many drugs are in development for Lymphoma, Non-Hodgkin's?
BioSniper tracks 1 drug in development for Lymphoma, Non-Hodgkin's across 1 company.
How many clinical trials target Lymphoma, Non-Hodgkin's?
There are 2 clinical trials targeting Lymphoma, Non-Hodgkin's tracked by BioSniper.
What is the prevalence of Lymphoma, Non-Hodgkin's?
The estimated prevalence of Lymphoma, Non-Hodgkin's is approximately 56.0 per 100,000 population.
Deep-dive into Lymphoma, Non-Hodgkin's
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis